Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Xylem Inc. (XYL) SEC Filings & Earnings Calls

EquiReason read 15 Xylem Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-29 — Xylem Inc. files underwriting agreement and supplemental indenture for issuance of 5.250% Senior Notes due 2029, 5.450% Senior Notes due 2032, and 5.850% Senior Notes due 2037..

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

XYLXylem Inc.Follow XYL — free
Specialty Industrial Machinery · Industrials
—
Price chart with a free account
Market cap
25.4B
P/E TTM
25.9
Dividend yield
1.5%
52-week
—
Next earnings
27 Oct, in 3 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

29 Sep 20268-KXylem Inc. files underwriting agreement and supplemental indenture for issuance of 5.250% Senior Notes due 2029, 5.450% Senior Notes due 2032, and 5.850% Senior Notes due 2037.SEC ↗
9 Sep 20268-K · 1.01, 1.02, 2.03Xylem entered a $1.5B senior unsecured revolving credit facility (expandable to $2B), replacing a $1B facility. No borrowings outstanding. Used for working capital and general corporate purposes.open

Risks flagged

No borrowings outstanding; facility used for general corporate purposes

“No borrowings are outstanding under the 2026 Credit Agreement on the date hereof” · word for word
Read the original on SEC EDGAR ↗
18 Aug 20268-K · 5.02, 7.01Guidance: Reaffirmed Q3 and full-year 2026 guidanceopen

Guidance

Reaffirmed Q3 and full-year 2026 guidance

Company reaffirms previously issued guidance for Q3 and full year 2026, indicating stability.

Risks flagged

Transition risk from CFO departure, though mitigated by internal promotion and orderly transition

“CFO resignation to pursue other opportunity; transition period through mid-September”
Read the original on SEC EDGAR ↗
13 Aug 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportSEC ↗
28 Jul 202610-QXylem reported Q2 2026 revenue of $2.336B (+1.5% YoY), orders surged 42%, gross margin expanded 240bps, and backlog grew 5.9% YoY.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q2-2026$2.34B+2% y/y
Net income attributable to Xylem · Q2-2026$263M+16% y/y
Operating cash flow · H1-2026$398M+18% y/y
Backlog · 2026-06-30$5.32B+6% y/y
Orders · Q2-2026$3.09B+42% y/y
Gross margin · Q2-202641.2%
Adjusted EBITDA margin · Q2-202623.3%
Free cash flow · H1-2026$219M+30% y/y

Risks flagged

Inflation pressure on margins

“240 basis points of inflation” · word for word

Measurement and Control Solutions segment decline

“Measurement and Control Solutions revenue decreased $32 million, or 5.9%... organic revenue declines were driven by $7 million from the smart metering and other applications.” · word for word

Divestiture impact on revenue

“loss of revenue from divestitures of $31 million” · word for word
Read the original on SEC EDGAR ↗
28 Jul 20268-K · 2.02Xylem Q2 2026: revenue $2.3B (+2% reported, +1% organic), EPS $1.11 (+19%), adj. EPS $1.46 (+16%), orders $3.1B (+42%). FY26 guidance: revenue ~$9.2B (prev. 2-3% growth now ~2%), adj. EBITDA margin 23.1-23.5%, adj. EPS $5.55-$5.70 (raised fearningsopen

Figures in the filing · each found in the filing text

Revenue · Q2-2026$2.30B+2% y/y
Orders · Q2-2026$3.10B+42% y/y
Earnings per share · Q2-2026$1.11+19% y/y
Adjusted earnings per share · Q2-2026$1.46+16% y/y
Net income · Q2-2026$263M
Net income margin · Q2-202611.3%
Adjusted EBITDA margin · Q2-202623.3%
Adjusted net income · Q2-2026$345M

Guidance

FY26 revenue ~$9.2B (~2% reported, 2-3% organic vs prior 2-3% and 2-4%); FY26 adj. EBITDA margin 23.1-23.5% (90-130 bps expansion); FY26 adj. EPS $5.55-$5.70 (raised from $5.35-$5.60); FY26 free cash flow margin 10.2-11.0% (unchanged)

Xylem raised FY26 adjusted EPS guidance and narrowed revenue guidance, while expanding EBITDA margin expectations. Strong demand from AI infrastructure and industrial markets supports positive outlook.

Risks flagged

Lower volumes partially offset margin expansion, indicating some demand softness in certain areas.

“Productivity savings, strong price realization and mix drove the margin expansion, exceeding the impact of inflation and lower volumes.” · word for word

Increased income tax expense and loss on sale of businesses partially offset strong operational performance.

“Partially offset by increased income tax expense and loss on sale of businesses.” · word for word
Read the original on SEC EDGAR ↗
29 May 20268-K · 1.01, 2.03, 8.01Xylem issued $1.0B in senior notes: $500M 5.200% notes due 2033 and $500M 5.450% blue notes due 2036. Proceeds to refinance existing debt and for blue projects. Routine debt capital markets transaction.SEC ↗
28 Apr 20268-K · 2.02Revenue $2.10B (+3% y/y); Orders $2.20B (+3% y/y); Earnings Per Share (GAAP) $0.79 (+14% y/y); Guidance: FY revenue guidance raised to ~$9.2-$9.3B (from 1-3% reported to 2-3%); adj. EPS unchanged $5.35-$5.60earningsopen

Figures in the filing · each found in the filing text

Revenue · Q1-2026$2.10B+3% y/y
Orders · Q1-2026$2.20B+3% y/y
Earnings Per Share (GAAP) · Q1-2026$0.79+14% y/y
Adjusted Earnings Per Share · Q1-2026$1.12+9% y/y
Net Income Attributable to Xylem · Q1-2026$193M
Adjusted Net Income Attributable to Xylem · Q1-2026$272M
Adjusted EBITDA Margin · Q1-202620.6%

Guidance

FY revenue guidance raised to ~$9.2-$9.3B (from 1-3% reported to 2-3%); adj. EPS unchanged $5.35-$5.60

Xylem raised full-year revenue guidance slightly while maintaining EPS and margin guidance; Q1 execution solid.

Risks flagged

Organic revenue growth flat in Q1; macro uncertainty could impact future demand.

“Revenue of $2.1 billion, up 3% on a reported basis and flat organically.”
Read the original on SEC EDGAR ↗
28 Apr 202610-QRevenue $2.12B (+3% y/y); Net income attributable to Xylem $193M (+14% y/y); Adjusted EBITDA $437M (+3% y/y); Guidance: total revenue growth outlook raised to 2% to 3% (from prior); organic revenue growth maintained at 2% to 4%open

Figures in the filing · each found in the filing text

Revenue · Q1-2026$2.13B+3% y/y
Net income attributable to Xylem · Q1-2026$193M+14% y/y
Adjusted EBITDA · Q1-2026$437M+3% y/y
Orders · Q1-2026$2.23B+3% y/y
Backlog · 2026-03-31$4.71B-8% y/y
Gross margin · Q1-202637.8%
Adjusted EBITDA margin · Q1-202620.6%
Free cash flow · Q1-2026$18M
Operating cash flow · Q1-2026$108M+227% y/y

Guidance

total revenue growth outlook raised to 2% to 3% (from prior); organic revenue growth maintained at 2% to 4%

Xylem raised its total revenue growth outlook to 2-3% while maintaining organic revenue growth guidance of 2-4%, reflecting confidence despite macro uncertainty.

Risks flagged

Tariff uncertainty and potential refunds

“As of March 31, 2026, we have not recorded a receivable related to potential tariff refunds due to the uncertainty regarding the timing and amount of such refunds at this time.” · word for word

Geopolitical and trade uncertainty

“Our outlook is being provided in the context of the current volatility, including due to geopolitical, trade, macroeconomic and regulatory uncertainty.” · word for word
Read the original on SEC EDGAR ↗
30 Mar 2026DEF 14AXylem filed its 2026 Proxy Statement (DEF 14A), disclosing executive compensation, governance, and 2025 performance highlights.open

Figures in the filing · each found in the filing text

Revenue · FY2025$9.04B+6% y/y
Net Income · FY2025$957M+8% y/y
Adjusted EBITDA Margin · FY202522.2%
Backlog · FY2025$4.60B
Orders · FY2025$8.90B
Adjusted EPS · FY2025$5.08+19% y/y
Operating Cash Flow Margin · FY202513.7%
Adjusted Free Cash Flow Margin · FY202510.2%

Risks flagged

Integration and transformation execution risk

“Transformation will continue as we execute our ERP program, accelerate our 80/20 initiatives, and make thoughtful moves to optimize our portfolio.” · word for word

Macroeconomic and demand uncertainty

“A detailed discussion of risks and uncertainties that could cause actual results and events to differ materially from such forward-looking statements is included in 'Item 1A. Risk Factors'” · word for word
Read the original on SEC EDGAR ↗
25 Feb 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement)SEC ↗
25 Feb 202610-KRevenue $9.04B (+6% y/y); Net income attributable to Xylem $957M (+8% y/y); Adjusted earnings per share $5.08 (+19% y/y); Guidance: Backlog $4,615M; ~60% expected to convert to revenue in 2026. Restructuring savings $80-120M expected in 202open

Figures in the filing · each found in the filing text

Revenue · FY2025$9.04B+6% y/y
Net income attributable to Xylem · FY2025$957M+8% y/y
Adjusted earnings per share · FY2025$5.08+19% y/y
Adjusted operating margin · FY202517.8%
Gross margin · FY202538.5%
Orders · FY2025$8.90B+2% y/y
Backlog · FY2025$4.62B-9% y/y
Adjusted EBITDA · FY2025$2.01B+14% y/y
Free cash flow · FY2025$910M-3% y/y
Capital expenditures · FY2025$331M+3% y/y

Guidance

Backlog $4,615M; ~60% expected to convert to revenue in 2026. Restructuring savings $80-120M expected in 2026.

Backlog decline suggests near-term revenue headwind, but restructuring savings and margin expansion provide offset. Management tone positive based on strong margin performance and dividend increase.

Risks flagged

Tariff exposure on imported inputs

“While we may recover some cost increases through operational improvements, we are still exposed to pricing risk, including due to duty and tariff assessments by the U.S. or other governments on foreign imports.” · word for word

Backlog decline

“Total backlog was $4,615 million at December 31, 2025 and $5,070 million at December 31, 2024, a decrease of 9.0%.” · word for word

Emerging markets softness

“Organic growth in the U.S. and western Europe more than offsetting organic declines in the emerging markets.” · word for word
Read the original on SEC EDGAR ↗
10 Feb 20268-K · 2.02Revenue $2.40B (+6% y/y); Adjusted earnings per share $1.42 (+20% y/y); Orders $2.40B (+9% y/y); Guidance: 2026 revenue guidance $9.1-9.2B (+2-4% organic), adj. EPS $5.35-5.60earningsopen

Figures in the filing · each found in the filing text

Revenue · Q4-2025$2.40B+6% y/y
Adjusted earnings per share · Q4-2025$1.42+20% y/y
Orders · Q4-2025$2.40B+9% y/y
Adjusted EBITDA margin · Q4-202523.2%
Dividend per share · Q1-2026$0.43+8% y/y
Full-year revenue · FY2025$9.00B+6% y/y
Full-year adjusted EPS · FY2025$5.08+19% y/y

Guidance

2026 revenue guidance $9.1-9.2B (+2-4% organic), adj. EPS $5.35-5.60

Positive 2026 guidance with organic revenue growth of 2-4%, adjusted EBITDA margin expansion of 70-110bps, and free cash flow margin of 10.2-11%

Risks flagged

Tariff and macroeconomic headwinds: inflation, energy supply, supply chain shortages mentioned as risk factors

“manufacturing and operating cost increases due to macroeconomic conditions, including inflation, energy supply, supply chain shortages, logistics” · word for word
Read the original on SEC EDGAR ↗
28 Oct 20258-K · 2.02Revenue $2.30B (+8% y/y); Earnings per share $0.93 (+4% y/y); Adjusted earnings per share $1.37 (+23% y/y); Guidance: Revenue guidance raised to ~$9.0B (5-6% reported vs prior 4-5%); adjusted EPS raised to $5.03-$5.08 from $4.70-$4.85earningsopen

Figures in the filing · each found in the filing text

Revenue · Q3-2025$2.30B+8% y/y
Earnings per share · Q3-2025$0.93+4% y/y
Adjusted earnings per share · Q3-2025$1.37+23% y/y
Adjusted EBITDA margin · Q3-202523.2%
Net income · Q3-2025$227M
Full-year 2025 revenue guidance · FY2025$9.00B
Full-year 2025 adjusted EPS guidance · FY2025$5.05

Guidance

Revenue guidance raised to ~$9.0B (5-6% reported vs prior 4-5%); adjusted EPS raised to $5.03-$5.08 from $4.70-$4.85

Raised full-year guidance on resilient demand and strong execution, with margin expansion driving EPS growth.

Risks flagged

Geopolitical, trade, macroeconomic, and regulatory uncertainty could impact future performance.

“Outlook is being provided in the context of the current volatility, including due to geopolitical, trade, macroeconomic and regulatory uncertainty.” · word for word
Read the original on SEC EDGAR ↗
28 Oct 202510-QQ3 2025 revenue grew 7.8% YoY to $2.27B, gross margin expanded 160bps to 38.9%, and adjusted EBITDA margin improved 200bps to 23.2%.earningsopen

Figures in the filing · each found in the filing text

Total Revenue · Q3-2025$2.27B+8% y/y
Organic Revenue Growth · Q3-20256.9%
Orders · Q3-2025$2.18B-1% y/y
Backlog · 2025-09-30$4.82B-8% y/y
Gross Margin · Q3-202538.9%
Operating Income · Q3-2025$334M+19% y/y
Net Income Attributable to Xylem · Q3-2025$227M+5% y/y
Adjusted EBITDA Margin · Q3-202523.2%
Adjusted Earnings Per Share · Q3-2025$1.37+23% y/y
Operating Cash Flow (YTD) · 9M-2025$698M+2% y/y

Risks flagged

Order Softness in Emerging Markets

“Organic growth for the transport application was $42 million, led by higher volume in the U.S., and strong backlog execution and order intake in western Europe. (Emerging markets softness noted in multiple segments)” · word for word

Backlog Decline

“Total backlog was $4,819 million at September 30, 2025, a decrease of $434 million, or 8.3%, as compared to September 30, 2024 backlog of $5,253 million.” · word for word

Restructuring Execution Risk

“We currently expect to incur between $90 and $100 million in restructuring costs for the full year.” · word for word
Read the original on SEC EDGAR ↗

Xylem Inc. — questions

What did Xylem Inc. file recently?
15 SEC filings in the last 12 months. Latest: 8-K on 2026-09-29 — Xylem Inc. files underwriting agreement and supplemental indenture for issuance of 5.250% Senior Notes due 2029, 5.450% Senior Notes due 2032, and 5.850% Senior Notes due 2037.

Every figure on this page comes from Xylem Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.